Literature DB >> 11257363

Hepatitis B: vaccination programmes in Europe--an update.

P Van Damme1.   

Abstract

In the eight years since the Global Advisory Group of the Expanded Program on Immunisation set 1997 as the target for integrating hepatitis B (HB) vaccination into national immunisation programs world-wide, more than 116 countries have included HB vaccine as part of their routine infant or adolescent immunisation programs. Meanwhile, many countries have performed economic evaluation studies, while others have initiated sero-epidemiological studies to generate input data for burden of disease calculation. These studies have indicated that epidemiological and economic arguments cannot be used to delay the implementation of universal hepatitis B vaccination. Some countries have improved their surveillance system and included viral hepatitis in the surveillance programs. Other have put hepatitis B vaccination on the political agenda. By the year 2000, following countries of the WHO European Region (51 countries) have implemented a universal hepatitis B immunisation programme: Andorra, Albania, Austria, Belarus, Belgium, Bulgaria, Estonia, France, Germany, Greece, Italy, Israel, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Luxembourg, Malta, Moldova, Monaco, Poland, Portugal, parts of the Russian Federation, Romania, Slovakia, Slovenia, San Marino, Spain, Switzerland, Turkey and Uzbekistan. The Netherlands and some other European countries are seriously studying the issues or are making budgetary provisions for introduction of HB vaccine into their vaccination programme. Most of the European countries, which now use the vaccine routinely, have started with adolescent or infant immunisation. Belgium (1999), France (1994) and Italy (1991) have begun with both adolescent and infant HB immunisation. France continues since 1st October 1998 with the infant immunisation programme only. The rewards of effective implementation of the programmes in these countries are becoming apparent; and their success offers an exemplary model for other countries. The deadline was 1997. Globally, work still remains to be done to support and implement interventions that will bring us closer to the WHO goal and to control, eliminate and eradicate hepatitis B in the coming generations at large. If all the 145 million infants born in 1991 had been vaccinated in this way, the number of chronic carriers would have been reduced by 7.5 million, and 1.8 million deaths prevented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257363     DOI: 10.1016/s0264-410x(00)00457-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  HPV vaccine: positive insights from universal adolescent HepB vaccination.

Authors:  J Claire Cameron; Lesley A Wallace; Syed Ahmed; Rina Duff; Martin Donaghy; David J Goldberg
Journal:  J Epidemiol Community Health       Date:  2007-12       Impact factor: 3.710

2.  Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization.

Authors:  Xue-Yan Liao; Zhen-Zuo Zhou; Fu-Bang Wei; Han-Ning Qin; Yuan Ling; Rong-Cheng Li; Yan-Ping Li; Yi Nong; Kui-Xia Sun; Jie Li; Hui Zhuang
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

3.  Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen.

Authors:  F Clement; P Dewint; G Leroux-Roels
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 4.  Prophylactic interventions on children: balancing human rights with public health.

Authors:  F M Hodges; J S Svoboda; R S Van Howe
Journal:  J Med Ethics       Date:  2002-02       Impact factor: 2.903

5.  Impact of universal preadolescent vaccination against hepatitis B on antenatal seroprevalence of hepatitis B markers in British Columbia women.

Authors:  Meenakshi Dawar; David M Patrick; Mark Bigham; Darrel Cook; Mel Krajden; Helen Ng
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

6.  Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study.

Authors:  L Bracciale; M Fabbiani; A Sansoni; L Luzzi; L Bernini; G Zanelli
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

Review 7.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Hepatitis B vaccination for sex workers: do outreach programmes perform better?

Authors:  R Mak; A Traen; M Claeyssens; L Van Renterghem; G Leroux-Roels; P Van Damme
Journal:  Sex Transm Infect       Date:  2003-04       Impact factor: 3.519

Review 9.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

10.  Substantial decline in hepatitis B virus infections following vaccine introduction in Tajikistan.

Authors:  Nino Khetsuriani; Faina Tishkova; Shamsidin Jabirov; Kathleen Wannemuehler; Saleem Kamili; Zulfiya Pirova; Liudmila Mosina; Eugene Gavrilin; Pavel Ursu; Jan Drobeniuc
Journal:  Vaccine       Date:  2015-06-10       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.